Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) Return on Invested Capital (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Return on Invested Capital for 5 consecutive years, with 1.57% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Invested Capital changed N/A to 1.57% in Q3 2025 year-over-year; TTM through Sep 2025 was 1.57%, a N/A change, with the full-year FY2019 number at 1.9%, up 100.0% from a year prior.
  • Return on Invested Capital was 1.57% for Q3 2025 at Outlook Therapeutics, down from 7.17% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 1.57% in Q3 2025 to a low of 1.57% in Q3 2025.